<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900886</url>
  </required_header>
  <id_info>
    <org_study_id>GEI-HCC-2010-01</org_study_id>
    <nct_id>NCT01900886</nct_id>
  </id_info>
  <brief_title>Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C</brief_title>
  <acronym>Perseo</acronym>
  <official_title>Prospective Observational Study to Assess Personality Disorders in Prison Populations for Hepatitis C Treatment. &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: Evaluate the prevalence of personality disorders in patients starting
      treatment for hepatitis C in the prison and determine their influence on the evolution of the
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives:

        -  Describe the management of patients with personality disorders on treatment for
           hepatitis C in the prison.

        -  Describe the characteristics of patients who discontinue the treatment and the reasons
           for stratifying by the presence of personality disorders.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response (SVR)</measure>
    <time_frame>RNA-VHC at weeks 24 or 48</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">263</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Personality Disorders in Prison</condition>
  <arm_group>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <description>Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Treatment as usual clinical practice</description>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Treatment as usual clinical practice</description>
    <arm_group_label>Pegasys, injection subcutaneous</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with chronic hepatitis C mono-or co-infected
        with HIV.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age.

          -  Patients with expected prison stay beyond the duration of follow-up period of the
             study.

          -  Patients with chronic HCV infection and detectable viral load to initiate treatment
             with standard therapy.

          -  Patients their written informed consent to participate in the study.

        Exclusion Criteria:

          -  Patients previously treated with Interferon (IFN) and Ribavirin (RBV).

          -  Patients can not read or understand a written questionnaire at the discretion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Marco, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Penitenciario de Hombres de Barcelona. Prisión Modelo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Penitenciario El Puerto III</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cadiz</state>
        <zip>11500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario de Albolote</name>
      <address>
        <city>Albolote</city>
        <state>Granada</state>
        <zip>18220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario Las Palmas</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Islas Canarias</state>
        <zip>35017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario de Tenerife</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38290</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario Ocaña I</name>
      <address>
        <city>Ocaña</city>
        <state>Toledo</state>
        <zip>45300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario de El Acebuche</name>
      <address>
        <city>Almeria</city>
        <zip>04071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario de Badajoz</name>
      <address>
        <city>Badajoz</city>
        <zip>06071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>14015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario de Topas</name>
      <address>
        <city>Salamanca</city>
        <zip>37799</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Penitenciario Sevilla I</name>
      <address>
        <city>Sevilla</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prison, disorder, hepatitis c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

